These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 16356956)

  • 1. Severe liver disease will increase unless injecting drug users are tested and treated.
    O'Dowd A
    BMJ; 2005 Dec; 331(7530):1422. PubMed ID: 16356956
    [No Abstract]   [Full Text] [Related]  

  • 2. Injecting behaviours and prevalence of hepatitis B, C and D markers in New Zealand injecting drug user populations.
    Kemp R; Miller J; Lungley S; Baker M
    N Z Med J; 1998 Feb; 111(1060):50-3. PubMed ID: 9539916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study.
    Judd A; Hickman M; Jones S; McDonald T; Parry JV; Stimson GV; Hall AJ
    BMJ; 2005 Jan; 330(7481):24-5. PubMed ID: 15533854
    [No Abstract]   [Full Text] [Related]  

  • 4. Impending concentrated HIV epidemic among injecting drug users in Central Bangladesh.
    Azim T; Alam MS; Rahman M; Sarker MS; Ahmed G; Khan MR; Rahman S; Rahman AS; Sack DA
    Int J STD AIDS; 2004 Apr; 15(4):280-2. PubMed ID: 15075028
    [No Abstract]   [Full Text] [Related]  

  • 5. Evidence for a substantial role of sharing of injecting paraphernalia other than syringes/needles to the spread of hepatitis C among injecting drug users.
    Mathei C; Shkedy Z; Denis B; Kabali C; Aerts M; Molenberghs G; Van Damme P; Buntinx F
    J Viral Hepat; 2006 Aug; 13(8):560-70. PubMed ID: 16901287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia.
    Maher L; Jalaludin B; Chant KG; Jayasuriya R; Sladden T; Kaldor JM; Sargent PL
    Addiction; 2006 Oct; 101(10):1499-508. PubMed ID: 16968352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outreach screening of drug users for cirrhosis with transient elastography.
    Moessner BK; Jørgensen TR; Skamling M; Vyberg M; Junker P; Pedersen C; Christensen PB
    Addiction; 2011 May; 106(5):970-6. PubMed ID: 21182552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute hepatitis B in injecting drug users is increasing as initiative to improve vaccine coverage begins.
    Commun Dis Rep CDR Wkly; 1999 May; 9(21):183, 186. PubMed ID: 10379092
    [No Abstract]   [Full Text] [Related]  

  • 9. Seroprevalence of hepatitis C in intravenous opioid users presenting in the early phase of injecting drug use in Singapore.
    Winslow M; Subramaniam M; Ng WL; Lee A; Song G; Chan YH
    Singapore Med J; 2007 Jun; 48(6):504-8. PubMed ID: 17538746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survey of injecting drug users' health shows mixed picture.
    Kmietowicz Z
    BMJ; 2010 Aug; 341():c4276. PubMed ID: 20693236
    [No Abstract]   [Full Text] [Related]  

  • 11. [Prevalence of chronic viral hepatitis in drug abusers].
    Osztrogonácz H; Gerevich J; Horváth G; Tolvaj G; Dávid K
    Orv Hetil; 2000 Apr; 141(14):715-8. PubMed ID: 10803013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The burden and recent epidemiological changes of the main chronic liver diseases in a Greek referral tertiary centre.
    Giannousis IP; Papatheodoridis GV; Deutsch MJ; Manolakopoulos SG; Manesis EK; Koskinas JS; Archimandritis AJ
    Eur J Gastroenterol Hepatol; 2010 Feb; 22(2):172-9. PubMed ID: 19738477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Capture--recapture and anchored prevalence estimation of injecting drug users in England: national and regional estimates.
    Hay G; Gannon M; MacDougall J; Eastwood C; Williams K; Millar T
    Stat Methods Med Res; 2009 Aug; 18(4):323-39. PubMed ID: 19036919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health-related quality of life in active injecting drug users with and without chronic hepatitis C virus infection.
    Dalgard O; Egeland A; Skaug K; Vilimas K; Steen T
    Hepatology; 2004 Jan; 39(1):74-80. PubMed ID: 14752825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment for hepatitis C virus infection among current injection drug users in Australia.
    Matthews G; Kronborg IJ; Dore GJ
    Clin Infect Dis; 2005 Apr; 40 Suppl 5():S325-9. PubMed ID: 15768342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C management: the challenge of dropout associated with male sex and injection drug use.
    Lowry DJ; Ryan JD; Ullah N; Kelleher TB; Crowe J
    Eur J Gastroenterol Hepatol; 2011 Jan; 23(1):32-40. PubMed ID: 21048503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The risk of HIV and HCV infections among injection drug users in northeast India.
    Mahanta J; Borkakoty B; Das HK; Chelleng PK
    AIDS Care; 2009 Nov; 21(11):1420-4. PubMed ID: 20024719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An evidence synthesis approach to estimating Hepatitis C prevalence in England and Wales.
    De Angelis D; Sweeting M; Ades A; Hickman M; Hope V; Ramsay M
    Stat Methods Med Res; 2009 Aug; 18(4):361-79. PubMed ID: 19036917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical management of drug addicts infected with human immunodeficiency virus and hepatitis C virus.
    Khalsa JH; Vocci F
    J Addict Dis; 2008; 27(2):1-10. PubMed ID: 18681186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales.
    Sutton AJ; Gay NJ; Edmunds WJ; Hope VD; Gill ON; Hickman M
    BMC Infect Dis; 2006 Jun; 6():93. PubMed ID: 16762050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.